Phase III study evaluating oral rimegepant 75mg for prevention of migraine meets primary endpoint
The RCT (n=695) reports those receiving rimegepant 75mg every other day experienced a statistically significant 4.5 day reduction from baseline in monthly migraine days, vs 3.7 day reduction in the placebo group (p=0.0176).
Source:
Biospace Inc.
SPS commentary:
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist, currently licensed in the USA for the treatment of acute migraine.